Theratechnologies Inc T.TH

Recruiting

[scarlet1967]

“What we are studying

We are doing this research study to find out if a drug called Tesamorelin can help people with nonalcoholic fatty liver disease (NAFLD). We have found that, on average, people with obesity have lower levels of growth hormone. Low levels of growth hormone may be related to developing NAFLD. Growth hormone is a hormone that helps children grow, and, in children and adults, regulates how the body uses and stores fat. Tesamorelin, the drug we are studying, increases the body’s growth hormone secretion. We would like to see if tesamorelin can reduce liver fat and improve liver health in adults who have NAFLD.”

 

https://rally.massgeneralbrigham.org/study/ghrh4nafld

[Lee430]

Is this the start of plan C for NASH apporval ?

[scarlet1967]

This study is targeting one of serious co morbidities of NAFLD. Point is for now all the focus is on cancer but let's remember they have another asset and a great drug(Egrifta).

[SPCEO1]

Looks like Dr, Grinspoon has gotten tired of waiting and went back to the NIH to fund this trial and keep things on Egrifta moving along. Since NAFLD is not yet something the FDA will approve a drug for, I suppose he is hoping whatever this trial discovers will change that attitude. Or, he may not really care that much about drug approval and is simply trying to push the science forward in the

[jfm1330]

If Grinspoon is disapointed, it should not only be about Thera. Right now the whole pharma world is saying no to tesamorelin in NASH. It's a gamble nobody is willing to take considering the costs. Also, maybe, considering the regulatory landscape to get a NASH drug approved.

[qwerty22]

When you click on the clinicaltrials.gov link it's a trial that first got posted in 2017 and has a start date of 2019 and a completion date of 2024. Nothing to do with THTX's inability to get things moving. https://clinicaltrials.gov/ct2/show/NCT03375788